{"disease":{"id":"immunoglobulin-a-nephropathy-igan","name":"immunoglobulin a nephropathy igan"},"drugs":{"marketed":[{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."},{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06291376","title":"Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":510,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06935357","title":"A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04287985","title":"Safety and Efficacy Study of VIS649 for IgA Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Visterra, Inc.","has_results":true},{"nct_id":"NCT05097989","title":"Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":100,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07474636","title":"Efficacy and Safety Study of HS-10542 for IgA Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03719443","title":"First in Human Study to Assess Safety of VIS649 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Visterra, Inc.","has_results":true},{"nct_id":"NCT07146906","title":"A Study to Assess the Effects of Zigakibart on IgA Nephropathy.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06994845","title":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07522099","title":"Chinese Adults With Kidney Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07498335","title":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05534919","title":"Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Everest Medicines (Singapore) Pte. Ltd.","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}